Background: A number of anaemic cancer patients are not responsive to treatment with recombinant human erythropoietin (rHuEPO). The aim of the present study is to investigate whether serum levels of tumour necrosis factoralpha (TNF-a), interleukin (IL)-1b, IL-6 and additional laboratory parameters, together with clinical variables, can predict the clinical outcome of treatment with rHuEPO in anaemic cancer patients.
introduction
Management of cancer-related anaemia is of primary importance for improving the quality of life of cancer patients [1] [2] [3] . Anaemia gives rise to several symptoms such as exhaustion, fatigue, impaired concentration and respiratory distress. This leads to a decrease in physical and mental capacity, increases the stress associated to the treatment and influences the decision of patients to discontinue chemotherapy [4, 5] . Red blood cell (RBC) transfusions and erythropoiesisstimulating agents (ESAs) are the only options available for patients with cancer-related anaemia in treatment with chemo-/radiotherapy [1, 2, [4] [5] [6] . ESAs include three main types of recombinant human erythropoietin (rHuEPO), epoetin alfa, epoetin beta and darbepoetin alfa, which regulate the proliferation, maturation and differentiation of RBCs. Recent publications and Food and Drug Administration (FDA) communications have increased the level of concern related to adverse effects of ESAs but these compounds are still indicated to treat anaemia caused by chemotherapy [7] . In addition, a large per cent of patients treated with ESAs do not respond positively to the treatment [6, 8, 9] . Thus, clinical or laboratory parameters that can early predict the outcome of treatment with ESAs are urgently needed in order to avoid the risks linked to the inappropriate administration of these drugs.
Several authors have previously reported that resistance to ESAs depends on an inadequate production of endogenous erythropoietin and serum cytokines concur to determine this alteration [9, 10] . The inhibition of endogenous erythropoietin production by inflammatory cytokines has been described in vitro [11] [12] [13] and tumour necrosis factor-alpha (TNF-a) can inhibit the release of iron from the reticuloendothelial system, inducing anaemia [14, 15] . Moreover, increased levels of some of these molecules have been correlated to the partial failure of exogenously administered erythropoietin in cancer patients [8, 15] . Aim of the present study is to evaluate whether high serum levels of TNF-a, IL-1b and IL-6 and further laboratory and clinical parameters can predict the outcome of treatment with ESAs in anaemic cancer patients.
patients and methods
patients analysed and treatment
This study was carried out before the publication of FDA recommendations concerning the use of ESAs [7] and was approved by the Institutional Review Board of the San Pietro FBF Hospital. We enrolled 35 cancer patients and 25 healthy controls. The study included patients affected by chemotherapy-associated anaemia with a level of haemoglobin (Hb) concentrations £11.0 g/dl, at least 12 weeks of cytotoxic chemotherapy planned regardless of schedule and legal age at the time of obtaining the informed consent (Table 1) .
Patients received epoetin alfa s.c. (EprexÒ Ortho Biotech/Janssen Cilag, New Brunswick, NJ) as soon as their Hb level decreased £11.0 g/dl. Treatment consisted of 150 IU/kg of epoetin alfa three times weekly for 12 weeks. If by week 6, the Hb level failed to improve by at least 2 g/dl above baseline, the dosage was increased to 300 IU/kg s.c. All patients filled out the Brief Fatigue Inventory (BFI), a questionnaire for the self-evaluation of the level of cancer-related fatigue (CRF), before treatment [16] . After the questionnaires had been completed, blood samples were collected. Transfusions of RBCs were allowed during the study but avoided in patients with a Hb level >8 g/dl, unless clinically indicated. An oral dose of 200 mg/day of elemental iron was recommended to maintain appropriate iron availability during the treatment.
cytokine determination
Blood samples were taken as soon as the Hb level of patients reached values £11.0 g/dl. Blood samples were centrifuged at 3000 g for 10 min, and serum samples were frozen at 280°C. TNF-a, IL-1b and IL-6 serum levels were evaluated by enzyme-linked immunosorbent assay. For the cytokine determination, hTNF-a, hIL-1b and hIL-6 immunoassay kits were used (TiterZymeÒ Immunoassay Kit, catalogue numbers 900-099; 900-132 and 900-033).
evaluation of efficacy and fatigue
The primary end point of this study was the evaluation of epoetin alfa therapeutic response. Patients were divided in three groups according to their treatment response (the change in Hb levels from baseline to the final value following 3 months of treatment). A complete response (CR) was defined as an increase in nontransfused Hb concentrations of at least 2 g/dl or a 100% decrease in RBC transfusion requirements over the treatment period. A partial response (PR) was an increase in nontransfused Hb values of 1-2 g/dl or a decrease in RBC transfusion requirements ‡50%. Any response less than a PR was considered no response (NOR). The secondary efficacy end point included the identification of a relationship between treatment outcome and baseline serum levels of TNF-a, IL-1b and IL-6. Finally, the tertiary efficacy end point was the self-assessment of CRF by means of the BFI [16] and the correlation of its baseline score with the treatment outcome.
statistical methodology
The cytokine serum levels and all the laboratory and clinical variables in the groups of Rs and NRs were compared using a student's t-test for continuous variables and by Fisher's exact test or Pearson chi-square test for discrete variables. To account for carrying out multiple comparisons, significant probability values obtained were corrected using the Bonferroni correction method. SPSS version 17 statistical package was used to carry out statistical analysis.
results

patient characteristics
Thirty-five cancer patients were enrolled in this study. Table 1 lists the demographic characteristics of the population and the variables related to disease. The mean age of the population was 60.5 (52-75) years and there were no differences between males and females. Twenty-six per cent of the patients had a poor Eastern Cooperative Oncology Group (ECOG) performance status (PS) at the time of the study and 50% were diagnosed with an early stage of disease. Note that, we have categorised the patients by PS as either good (ECOG score between 0 and 1) or poor (ECOG scores between 2 and 4) and by stage of disease as either early (stage I-II) or advanced (stage III-IV).
correlation of laboratory and clinical variables with treatment outcome
Of the 35 cancer patients, only 33 completed the treatment and were evaluated. One patient discontinued rHuEPO because of the occurrence of thrombophlebitis, while one patient was not compliant with the treatment. Eight patients showed a CR, 5 patients a PR and 20 patients NOR (Table 2) . Of the patients who obtained a response, eight exhibited an optimal response at the dose of 150 IU/kg s.c. and were maintained with this dose, whereas the other five patients achieved a response only at the higher dose of 300 IU/kg s.c. (Table 2 ). First, we evaluated the cytokine levels of cancer patients and health controls.
As expected, TNF-a, IL-1b and IL-6 levels were significantly higher in anaemic cancer patients, than in the control group Additionally, when evaluated according to age and sex, there were no differences between levels of TNF-a, IL-1b and IL-6 in the treated population. Secondly, we evaluated the levels of TNF-a, IL-1b and IL-6 in the cancer patient population, between the categories of responders (CR + PR) and nonresponders. Cancer patients who responded to epoetin alfa had lower medium levels of TNF-a and IL-6 compared with patients who did not respond (TNF-a: 3.1 6 2.6 and IL-6: 1.2 6 0.52 versus 8.3 6 3.9 and 3.2 6 2.4 pg/ml, respectively). These differences were statistically significant even after correction with the Bonferroni method for multiple comparisons (Table 3 and Figures 1 and 2 ). Rs had higher levels of IL-1b compared with NRs (7.6 6 3.6 versus 5.4 6 4.6), but this difference was not significant (IL-1b, P = 0.1). Since PS and type of treatment in the selected patients' population may have influenced our findings, underestimating our results, we decided to repeat our analysis, eliminating those patients having high PS and that were receiving platinum-based treatment at the time of the cytokine determination. Indeed, patients with PS of four are often refractory to any kind of treatment. Similarly, patients receiving platinum derivatives are unlikely to respond to rHuEPO administration in consideration of the high bone marrow toxicity of these regimens. After the exclusion of these patients, Rs increased to 52% (12 of 23). Indeed, only 2 of 33 patients presented a PS equal to four and 8 patients of 33 were treated with platinum derivatives. In this population, Rs still presented lower medium levels of cytokines than NRs (TNF-a: 3.05 6 2.4, IL-6: 1.2 6 0.5 and IL-1b: 8.0 6 3.69 versus 7.24 6 3.9, 3.87 6 2.8 and 5.18 6 4.5 pg/ml, respectively). These differences were statistically significant with the exception of IL-1b (TNF-a: P = 0.0073, IL-6: P = 0.0098 and IL-1b: P = 0.1139) (supplemental Figure S1 , available at Annals of Oncology online). In the univariate analysis, no differences were observed in the levels of TNF-a, IL-1b and IL-6 between patients with poor or good PS and early or advanced stage of disease. Moreover, no differences in the basal levels of RBCs, Hb and lactate dehydrogenase were observed in the categories of NRs and Rs even after doubling the dose of rHuEPO to 300 IU/kg s.c. (see Table 3 ). Finally, patients with good PS and a BFI score £6 (nonfatigued patients) presented similar levels of TNF-a, IL-1b and slightly higher level of IL-6 than patients with poor PS and BFI score ‡6, but these differences were not statistically significant after correction with the Bonferroni method for multiple comparisons.
fatigue prevalence and severity
By using the BFI, 70% of the patients reported their fatigue as severe ( ‡6 on 0-10 scale). The mean score of fatigue worst was 
6).
When we evaluated the BFI scores in relation to response obtained after rHuEPO administration, no differences were seen in all the items of the general and daily-activity BFI between Rs and NRs to epoetin alfa administration (see Table  4 ). This indicates that a higher BFI score at the baseline (fatigued cancer patients) does not predict a negative outcome for rHuEPO administration. Interestingly, in our sample, fatigued cancer patients (BFI ‡ 6) presented higher levels of TNF-a and IL-1b than nonfatigued cancer patients (BFI ‡ 6). However, this difference was not statistically significant.
discussion
Several studies have previously demonstrated that rHuEPO is effective in treating anaemia in cancer patients [1] [2] [3] 17] . However, recent findings have increased the concern about the safety of ESAs [18] . In response to these findings, the FDA has released a Public Health Advisory and a clinical alert for doctors, recommending caution in using ESAs in patients receiving chemotherapy (www.fda.gov/cder/drug/advisory/ RHE2007.htm). Additionally, a considerable proportion of anaemic cancer patients are ultimately refractory to treatment with rHuEPO [8] . The overall response rate achieved by rHuEPO in anaemic cancer patients is 50% [6, 8] . Patients who fail to respond to rHuEPO experience not only the unnecessary burden of frequent s.c. injections but also the disappointment of unfulfilled hopes. Thus, the expansion of a not-justified therapy risks to excessively increasing the health care costs, hanging unjustly over the health community resources. In order to direct the potential benefit of rHuEPO treatment towards the greatest response, it would be useful to identify NRs before starting treatment or within the first few weeks of therapy. The aim of our study was to investigate the clinical utility of using pretreatment cytokine levels to predict the response to treatment with rHuEPO. Various cytokines have been described to influence erythropoiesis, leading to ESA resistance [1, 9, 11-13, 15, 19, 20] . These cytokines are involved in both inhibition of erythroid progenitors and erythropoietin production, as well as impairment of iron release [9] . IL-lb, TNF-a and interferon-c have been reported to suppress erythropoiesis by acting synergistically [12, 19] . Other authors have reported that IL-1a and IL-1b can suppress the colonyforming units (erythroid) [14, 20] . In addition, several research groups have recently reported that IL-6 acts as one of the major regulators of the hepatic hormone hepcidin, an antimicrobial peptide which can significantly affect erythropoiesis. Hepcidin is a regulator of iron metabolism and inhibits iron absorption and recycling from erythrophagocytosis by macrophages [21] . High circulating levels of IL-6 can increase the expression of hepcidin. Excessive hepcidin and TNF-a production explains the relative deficiency of iron during inflammatory states, resulting in the anaemia of chronic inflammation [21, 22] . Only few studies have investigated in vivo the role of serum cytokines as early predictors of treatment outcome in patients treated with ETs. Ludwig et al. [23] included TNF-a, IL-1b and IL-6 in a list of several factors examined as early predictors of ET response without observing a clear correlation between these cytokines and treatment responses. Two additional studies in patients affected by myelodysplastic syndrome (a pre-neoplastic condition) have investigated the role of cytokines as early predictors of rHuEPO outcome, reporting a positive correlation [24, 25] . original article
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In this study, we have prospectively examined the serum levels of TNF-a, IL-6 and IL-1b in a group of patients affected by solid tumours, receiving treatment with rHuEPO and standard chemotherapy, and we have reported a clear correlation between high basal levels of TNF-a and IL-6 and poor treatment outcome.
These results indicate that TNF-a and IL-6 may inhibit bone marrow erythropoiesis in anaemic cancer patients leading to ET resistance in vivo. Thus, treatments that block or reduce the level of circulating cytokines may be associated to ET administration to reverse the suppression of the multi-potent bone marrow stem cells in these patients. Additional laboratory variables tested in our study included Hb level and RBCs. Although both were decreased in NRs when compared with Rs, they were not significantly correlated with response to rHuEPO.
We had also evaluated whether a higher BFI score at the baseline could predict a negative rHuEPO outcome in our cancer population. BFI has shown to be a reliable instrument that allows a quick assessment of fatigue in cancer patients [4, 16] . A BFI score ‡6 is highly indicative of patients affected with CRF [16] . Several evidences have also showed that serum cytokines are increased in patients with severe fatigue and suffering from other cancer-related symptoms [26, 27] . It is therefore reasonable to hypothesise that a poor BFI score at baseline should predict a negative treatment outcome of ET therapy. Although we have confirmed that the levels of cytokines in patients with fatigue (BFI ‡ 6) are higher than in patients with low or no fatigue (BFI < 6), these data were not statistically significant. We are aware that the limited size of our study group introduces a limitation to drawing a definitive conclusion regarding some of our observations. However, whether these observations are confirmed in a larger clinical trial, the determination of circulating cytokines before the beginning of treatment should resolve many issues associated with the ET administration in anaemic cancer patients. 
